Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

abstract：BACKGROUND:Estimating an individual woman's absolute risk for breast cancer is essential for decision making about screening and preventive recommendations. Although the current standard, the Gail model, is well calibrated in populations, it performs poorly for individuals. Mammographic breast density (BD) may improve ...

journal_title：Breast cancer research and treatment

authors： Tice JA,Cummings SR,Ziv E,Kerlikowske K

更新日期：2005-11-01 00:00:00

abstract：:Fibroblast growth factor receptor 2 (FGFR2) is a member of a receptor tyrosine kinase gene superfamily, involved in cell growth, invasiveness, motility, and angiogenesis, which has attracted considerable attention as a candidate gene for breast cancer (BC) since it was first identified through genome-wide association ...

journal_title：Breast cancer research and treatment

authors： Wang H,Yang Z,Zhang H

更新日期：2013-01-01 00:00:00

abstract：:Fresh organically grown pomegranates (Punica granatum L.) of the Wonderful cultivar were processed into three components: fermented juice, aqueous pericarp extract and cold-pressed or supercritical CO2-extracted seed oil. Exposure to additional solvents yielded polyphenol-rich fractions ('polyphenols') from each of th...

journal_title：Breast cancer research and treatment

authors： Kim ND,Mehta R,Yu W,Neeman I,Livney T,Amichay A,Poirier D,Nicholls P,Kirby A,Jiang W,Mansel R,Ramachandran C,Rabi T,Kaplan B,Lansky E

更新日期：2002-02-01 00:00:00

abstract：:A detailed analysis of the immune system response has been performed during the development and progression of dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors. For this aim, a number of immune parameters (thymocyte and splenocyte proliferative response to T-dependent mitogens, antibody production, lymphocy...

journal_title：Breast cancer research and treatment

authors： Gallo F,Morale MC,Sambataro D,Farinella Z,Scapagnini U,Marchetti B

更新日期：1993-09-01 00:00:00

abstract：:Estrogen receptor beta (ERbeta) is widely expressed in mammary epithelium. ERbeta expression is reported to decline during carcinogenesis of the breast and other tissues. In this study, we examined the consequences of a loss of ERbeta expression in mammary epithelial cells. We knocked down ERbeta transcript levels in ...

journal_title：Breast cancer research and treatment

authors： Treeck O,Lattrich C,Springwald A,Ortmann O

更新日期：2010-04-01 00:00:00

abstract：:We have measured the levels of tamoxifen and three of its metabolites in the blood of patients receiving tamoxifen alone or combination therapy with tamoxifen and medroxyprogesterone acetate. Our results indicate that addition of the progestogen significantly alters the metabolism of tamoxifen over a six-month period....

journal_title：Breast cancer research and treatment

authors： Reid AD,Horobin JM,Newman EL,Preece PE

更新日期：1992-01-01 00:00:00

abstract：:The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described previously (Kaufman et...

journal_title：Breast cancer research and treatment

authors： Cortes J,Hudgens S,Twelves C,Perez EA,Awada A,Yelle L,McCutcheon S,Kaufman PA,Forsythe A,Velikova G

更新日期：2015-12-01 00:00:00

abstract：:Axillary management in breast cancer is becoming increasingly conservative. This approach is based on the identification of low axillary burden on sentinel node biopsy (SNB). The modern practice of routine pre-operative axillary ultrasound has meant that patients are 'fast tracked' to axillary node clearance (ANC) in ...

journal_title：Breast cancer research and treatment

authors： Ahmed M,Jozsa F,Douek M

更新日期：2017-09-01 00:00:00

abstract：:Kinase suppressor of Ras 1 (KSR1) has been implicated in tumorigenesis in multiple cancers, including skin, pancreatic and lung carcinomas. However, our recent study revealed a role of KSR1 as a tumour suppressor in breast cancer, the expression of which is potentially correlated with chemotherapy response. Here, we a...

journal_title：Breast cancer research and treatment

authors： Zhang H,Angelopoulos N,Xu Y,Grothey A,Nunes J,Stebbing J,Giamas G

更新日期：2015-06-01 00:00:00

abstract：:Endocrine therapy is an important therapeutic approach for the treatment of oestrogen receptor (ER)-positive breast cancer. However, a number of these endocrine therapies can fail when the tumour loses its ER expression during treatment. To date, few studies have explored the potential clinical significance of traditi...

journal_title：Breast cancer research and treatment

authors： Zhang B,Zhang X,Tang B,Zheng P,Zhang Y

更新日期：2012-11-01 00:00:00

abstract：PURPOSE:To compare the prognostic significance of proliferation, as assessed by Ki67 expression, in breast cancer before and after neoadjuvant chemotherapy. METHODS:A retrospective search of a prospectively maintained clinical database was performed to identify patients treated with neoadjuvant chemotherapy at the Roy...

journal_title：Breast cancer research and treatment

authors： Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

更新日期：2009-07-01 00:00:00

abstract：:Previous investigations into the relationship of CAG-repeat lengths in the androgen receptor (AR) gene to female breast cancer (BC) have yielded somewhat confusing results. Decreased AR transactivational activity lowers androgen:estrogen balance, and may thereby effect functional hyperestrogenicity. This may promote t...

journal_title：Breast cancer research and treatment

authors： Elhaji YA,Gottlieb B,Lumbroso R,Beitel LK,Foulkes WD,Pinsky L,Trifiro MA

更新日期：2001-11-01 00:00:00

abstract：:The c.156_157insAlu BRCA2 mutation has so far only been reported in hereditary breast/ovarian cancer (HBOC) families of Portuguese origin. Since this mutation is not detectable using the commonly used screening methodologies and must be specifically sought, we screened for this rearrangement in a total of 5,443 suspec...

journal_title：Breast cancer research and treatment

authors： Peixoto A,Santos C,Pinheiro M,Pinto P,Soares MJ,Rocha P,Gusmão L,Amorim A,van der Hout A,Gerdes AM,Thomassen M,Kruse TA,Cruger D,Sunde L,Bignon YJ,Uhrhammer N,Cornil L,Rouleau E,Lidereau R,Yannoukakos D,Pertesi M

更新日期：2011-06-01 00:00:00

abstract：:The activity of selective estrogen receptor modulators (SERMs) is not fully explained by an estrogen receptor (ER) switch model that simply turns estrogen activity on or off. A better understanding of the mechanisms involved in estrogen signaling and the development of drug resistance could help stratify patients into...

journal_title：Breast cancer research and treatment

authors： McCafferty MP,McNeill RE,Miller N,Kerin MJ

更新日期：2009-08-01 00:00:00

abstract：:Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive invasive ductal carcinoma accounts for ~45 % of invasive breast cancer (BC) diagnoses in the U.S. Despite reductions in BC mortality attributable to mammography screening and adjuvant hormonal therapy, an important challenge remains the development of...

journal_title：Breast cancer research and treatment

authors： Buas MF,Rho JH,Chai X,Zhang Y,Lampe PD,Li CI

更新日期：2015-09-01 00:00:00

abstract：:Resistance of breast cancers to targeted hormone receptor (HR) or human epidermal growth factor receptor 2 (HER2) inhibitors often occurs through dysregulation of the phosphoinositide 3-kinase, protein kinase B/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Presently, no targeted therapies exist for breast...

journal_title：Breast cancer research and treatment

authors： Wilson-Edell KA,Yevtushenko MA,Rothschild DE,Rogers AN,Benz CC

更新日期：2014-04-01 00:00:00

abstract：:Although there is abundant information about the independent effects of estrogen receptor (ER) and progesterone receptor (PR) on outcomes of breast cancer, comparatively little is known about the impact of joint (ER+PR+, ER+PR-, ER-PR+ and ER-PR-) ERPR expression. The purpose of this study was to evaluate the prognost...

journal_title：Breast cancer research and treatment

authors： Ouyang Y,Li D,Pater JL,Levine M

更新日期：2005-07-01 00:00:00

abstract：BACKGROUND:The aromatase inhibitors (AIs) are increasingly surpassing tamoxifen as the endocrine treatment of choice for postmenopausal breast cancer patients. With their increasing use, there is concern that they are being inadvertently prescribed to pre- and peri-menopausal women. METHODS:As part of a continuing med...

journal_title：Breast cancer research and treatment

authors： Gainford MC,McCready D,Clemons M

更新日期：2006-04-01 00:00:00

abstract：PURPOSE:To investigate the clinical impact of FDG-PET/CT for staging and treatment planning in high-risk primary breast cancer. METHODS:Women with high-risk primary breast cancer were enrolled between September 2017 and August 2019 at Odense University Hospital, Denmark. Conventional mammography with/without MRI was p...

journal_title：Breast cancer research and treatment

authors： Vogsen M,Jensen JD,Christensen IY,Gerke O,Jylling AMB,Larsen LB,Braad PE,Søe KL,Bille C,Ewertz M,Hildebrandt MG

更新日期：2021-01-01 00:00:00

abstract：:Knowledge of the family history of cancer may significantly influence diagnosis and surgical management. Hereditary breast cancer (HBC) is common and accounts for approximately 9% of the total breast cancer burden. The pattern of HBC's natural history, including age of onset, increased incidence of bilaterality, integ...

journal_title：Breast cancer research and treatment

authors： Lynch HT,Conway T,Fitzgibbons R Jr,Schreiman J,Watson P,Marcus J,Fitzsimmons ML,Lynch JF

更新日期：1988-12-01 00:00:00

abstract：PURPOSE:The optimal management of breast cancer patients with a positive sentinel lymph node (SLN) who undergo mastectomy remains controversial. This study aimed to describe treatment patterns of patients with positive SLNs who undergo mastectomy using a large population-based database. METHODS:The NCDB was queried fo...

journal_title：Breast cancer research and treatment

authors： Weiss A,Lin H,Babiera GV,Bedrosian I,Shaitelman SF,Shen Y,Kuerer HM,Mittendorf EA,Caudle AS,Hunt KK,Hwang RF

更新日期：2019-07-01 00:00:00

abstract：PURPOSE:Myeloperoxidase (MPO) is an enzyme secreted by neutrophil granulocytes as a result of phagocytosis during inflammation. In colorectal cancer, tumour infiltration by MPO expressing cells has been shown to be independently associated with a favourable prognosis. In this study, we explored the role of MPO-positive...

journal_title：Breast cancer research and treatment

authors： Zeindler J,Angehrn F,Droeser R,Däster S,Piscuoglio S,Ng CKY,Kilic E,Mechera R,Meili S,Isaak A,Weber WP,Muenst S,Soysal SD

更新日期：2019-10-01 00:00:00

abstract：:The taxanes and anthracyclines have emerged as the most active agents for treating women with advanced breast cancer. As such, investigation of the two drug classes in combination regimens has been eagerly pursued. The rationale for combining docetaxel with an anthracycline includes high clinical activity of each indi...

journal_title：Breast cancer research and treatment

authors： Nabholtz JM

更新日期：2003-01-01 00:00:00

abstract：:Theophylline reduces cell number in MDA-MB-231 cells through mechanisms over and above phosphodiesterase inhibition. In the current study, we used an intracellular fluorescent dye to show that theophylline and, to a much greater extent, 3-isobutyl-1-methylxanthine, evoke the generation of reactive oxygen species and a...

journal_title：Breast cancer research and treatment

authors： Crumpton TL,Seidler FJ,Slotkin TA

更新日期：2001-03-01 00:00:00

abstract：:The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfr...

journal_title：Breast cancer research and treatment

authors： Nitz U,Gluz O,Christgen M,Kates RE,Clemens M,Malter W,Nuding B,Aktas B,Kuemmel S,Reimer T,Stefek A,Lorenz-Salehi F,Krabisch P,Just M,Augustin D,Liedtke C,Chao C,Shak S,Wuerstlein R,Kreipe HH,Harbeck N

更新日期：2019-05-01 00:00:00

abstract：PURPOSE:The RAS family comprises three proto-oncogenes (H-RAS, K-RAS, and N-RAS) and is among the most widely studied of oncogenes. The present study aimed at investigating the clinical relevance of mRNA levels of the three isoforms in a large group of breast cancer patients with a long-term follow-up. METHODS:198 pre...

journal_title：Breast cancer research and treatment

authors： Banys-Paluchowski M,Milde-Langosch K,Fehm T,Witzel I,Oliveira-Ferrer L,Schmalfeldt B,Müller V

更新日期：2020-01-01 00:00:00

abstract：:Tamoxifen is metabolized into endoxifen, a potent antagonist of the estrogen receptor, in part through cytochrome p450 (CYP) 2D6. Genotypic variation in CYP2D6 affects endoxifen levels, and some have argued that patients who do not efficiently metabolize tamoxifen might wish to consider alternative hormonal treatments...

journal_title：Breast cancer research and treatment

authors： Ruddy KJ,Desantis SD,Gelman RS,Wu AH,Punglia RS,Mayer EL,Tolaney SM,Winer EP,Partridge AH,Burstein HJ

更新日期：2013-10-01 00:00:00

abstract：:To employ in vivo imaging and histological techniques to identify and quantify vascular changes early in the course of treatment with trastuzumab in a murine model of HER2+ breast cancer. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used to quantitatively characterize vessel perfusion/permeabilit...

journal_title：Breast cancer research and treatment

authors： Sorace AG,Quarles CC,Whisenant JG,Hanker AB,McIntyre JO,Sanchez VM,Yankeelov TE

更新日期：2016-01-01 00:00:00

abstract：:The ability of the antiangiogenic agents TNP-470 and minocycline, singly or in combination, to potentiate the antitumor effects of several cytotoxic therapies was assessed in the murine EMT-6 mammary carcinoma as well as in two drug resistant sublines of that tumor designated EMT-6/CTX and EMT-6/CDDP. The antiangiogen...

journal_title：Breast cancer research and treatment

authors： Teicher BA,Holden SA,Dupuis NP,Kakeji Y,Ikebe M,Emi Y,Goff D

更新日期：1995-01-01 00:00:00

abstract：:The 2008 Physical Activity (PA) Guidelines recommend engaging in at least 2.5 h (10 MET-hours/week) of moderate intensity PA per week (defined as 4 METs) to reduce risk of morbidity and mortality. This analysis was conducted to investigate whether this recommendation can be extended to breast cancer survivors. Data fr...

journal_title：Breast cancer research and treatment

authors： Beasley JM,Kwan ML,Chen WY,Weltzien EK,Kroenke CH,Lu W,Nechuta SJ,Cadmus-Bertram L,Patterson RE,Sternfeld B,Shu XO,Pierce JP,Caan BJ

更新日期：2012-01-01 00:00:00